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The health needs of pregnant opioid dependent women are increasingly being recognized by health care professionals. These women
generally receive limited antenatal care. Maternal and neonatal outcomes are also poorer compared to non-drug using women. The number of
pregnant opioid dependent women accessing drug treatment services in the Irish Republic has increased. A specialist Drug Liaison Midwife
service was created in March 1999 to liaise between the three Dublin Maternity hospitals and the Drug Treatment Services. This paper
surveys the first year of operation of one of these posts. It documents sociodemographic background, substance use, and medical histories of
these women in addition to maternal and neonatal outcomes. Higher maternal methadone dose was associated with an increased risk of
neonatal withdrawals among these women. The experience of this specialist liaison service indicates that it is possible to build effective
working relationships between opioid dependent pregnant women and the Obstetric and Drug services involved in their care. This has
resulted in benefit to these women, their children and the Irish Health Care system. D 2004 Elsevier Inc. All rights reserved.Keywords: Opioid dependent pregnant women; Drug Liaison Midwives; Maternal methadone dose; Neonatal withdrawals
1. Introduction to the appointment of Drug Liaison Midwives (DLM) to theThere has been an increasing recognition of the needs of
pregnant drug dependent women among professionals in-
volved in their care (Ebrahim & Gfroerer, 2003; Fischer,
2000). A recent report from the European Monitoring
Centre for Drugs and Drug Addiction (2000) has recom-
mended that their care be prioritized. The opioid using
population in the Irish Republic and those accessing treat-
ment are younger than other opioid dependent European
populations (Department of Tourism, Sport & Recreation,
2001). The number of dependent pregnant users accessing
treatment has increased (Moran, O’Brien, & Duff, 1997;
O’Brien, Moran, Kelleher, & Cahill, 2000). There has also
been an increase in the numbers of infants admitted to
Special Care Baby Units with a diagnosis of Neonatal
Abstinence Syndrome with obvious bed occupancy and
financial implications. This situation was the background0740-5472/04/$ – see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: mpscully75@aol.com (M. Scully).three Dublin maternity hospitals in March 1999.
Here we describe an analysis of the referrals to one of
these posts, attached to the Coombe Women’s Hospital
(CWH), a university teaching hospital located in the south
inner city area of Dublin that mainly serves patients from the
South Western Area Health Board.
1.1. Methadone treatment
The oral substitution agent methadone has been licensed
for the treatment of opioid dependence since the late 1960s.
It was, however, the early part of the 1990s that saw
considerable expansion of treatment services with the adop-
tion of a Harm Reduction approach by the Irish government.
An account of the development and adoption of Harm
Reduction in an Irish context has recently been outlined
by Barry (2002).
Oral substitution treatment is now more widely available.
The mainstay of treatment is oral methadone. All patients
commenced on methadone are registered on a Central
Treatment List and all have a designated treatment card
M. Scully et al. / Journal of Substance Abuse Treatment 26 (2004) 27–3328lodged with their dispensing outlet. All methadone treat-
ment is free.
An innovative shared care approach exists between spe-
cialist psychiatric substance misuse services and general
practice (Keenan & Barry, 1999). In general practice set-
tings, only specially trained general practitioners may pre-
scribe methadone for the treatment of opioid dependence.
These ‘‘level 1 doctors’’ are limited to prescribing for a
limited number of patients who are already stable on oral
methadone while level 2 doctors may both initiate metha-
done stabilization and continue to prescribe for a larger
number of patients on an extended basis. Each Health Board
serves a defined geographic catchment area. Each Health
Board has a specialist GP who coordinates general medical
input into the community treatment services with the local
Consultant Psychiatrist in Substance Misuse and the local
Liaison Pharmacist.
1.2. Maternal care for opiate-dependent pregnant women
In Dublin, access to treatment was prioritized for pregnant
opioid dependent women. The priority was designed to
engage the woman, to have her access both prenatal and drug
treatment services quickly, stabilize on oral methadone ther-
apy, and address other health and social care issues as
necessary. Stabilization of drug use was stressed and women
were encouraged to remain on oral methadone throughout
their pregnancy. Dose reduction or escalation was determined
by the prescribing doctor in collaboration with the woman.
Methadone doses were individualized to take account of
individual differences in tolerance and other medical issues
(e.g. other medications, HIV, or HCV status). Informed
consent to treatment was always sought and the women were
aware of their current dose of methadone at all times.
Stability of maternal drug use and engagement with
obstetric services were the major treatment priorities. The
option to detoxify as an inpatient or outpatient after the first
trimester existed, but women were not pressured to reduce
dose or to detoxify. Those who had difficulties stabilizing
were offered inpatient admission to a specialist drug depen-
dency unit to facilitate stabilization.
After an initial assessment by the DLM, those women not
in treatment were immediately offered a treatment place
depending on their needs as assessed at the interview with
the DLM. All cases were discussed with the Consultant
Psychiatrist in Substance Misuse from the relevant Sector
team. The settings available for drug treatment included a
tertiary treatment center, local methadone treatment centers,
and local GP practices where methadone dispensing oc-
curred in a local community pharmacy. All women had
prenatal booking appointments made with the obstetric
services. Some of these appointments were routine but the
facility accelerated appointments in cases where there
existed a clinical indication.
A considerable amount of time was spent by the DLM in
building working relationships with the women. Issuesaround confidentiality, contact with social services, etc.,
were explicitly dealt with and written permission was
obtained to authorize contact and disclosure of relevant
information. All the women signed a release of information
form authorizing the DLM to liaise between the services at
the CWH and the local Drugs service.
The current study aimed to document the numbers of
women using this new specialist service, and to gain
knowledge of their sociodemographic backgrounds and
substance use histories. We wanted to document the out-
comes for both the mothers and their infants and to look at
factors associated with good outcomes.2. Methods
The survey was retrospective and chart based. The Ethics
Committee at the CWH approved the research proposal.
Information was gathered from the files held by the DLM
using a questionnaire designed for the study. Obstetric and
neonatal data were obtained from the patient files held by the
Coombe Women’s Hospital. Additional data were gathered
from the patient files held by the Drugs service. Each
pregnancy was counted as a separate case for the purpose
of the analysis. Statistical analysis was undertaken using
SPSS version 10.3. Results
In the period from April 1999 to the end of April 2000
there were 111 referrals to the DLM. Two women became
pregnant twice during the study period and one woman had
twins. Percentages are presented in adjusted form (valid
percent) to take account of missing data.
3.1. Socio-demographic background
The mean age of this cohort was 23.8 years (range
17–32 years). The majority were unemployed. The mean
age of leaving full time education was 15.7 years (range
12–18 years). Thirty-nine women (43.8%) had one state
exam, although only 17 (19.1%) had completed the final
state exam. The majority were in relationships and 51
(48.1%) had drug-using partners. Forty-nine women
(47.6%) lived with a partner, 27 women (26.2%) lived with
their families and eight women (7.8%) described themselves
as homeless.
The mean number of previous pregnancies was 2.21
(range 0–7). The mean number of live births for the
sample was 0.9 (range 0–4 births). Fifty-four women had
never given birth previously (48.6%), 29 women had one
child (26.1%), 15 had two children and only 13 women
had three or more children. Only 21 women (20.8%)
reported that the pregnancy was planned. Only 15 women
reported using regular contraception. The majority of these
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(medroxyprogestrone acetate—a long acting parenteral
progestogen-only contraceptive).
3.2. Drug history
Eighty-three women were in substance abuse treatment at
the time of referral to the DLM. Their mean age of first
using heroin was 18.3 years (range 9–32 years). Their mean
age of first injecting heroin was 19.8 years (range 15–30
years) and the mean duration of injecting heroin use was
20.61 months (range 0–108 months) (Table 1). A history of
polysubstance use was common. Only three women did not
use tobacco while 34 (35.8%) used alcohol. Fifty-six
women (73.7%) gave histories of using benzodiazepines,
40 women (52.6%) of using cocaine, and 10 women
(22.7%) of using tricyclic anti-depressant drugs.
3.3. Forensic history
Fifteen women (17.6%) reported current charges at the
time of initial assessment by the DLM. Twenty-six women
(31.7%) reported a history of having at least one prior
conviction and 18 (22.5%) of them had been in prison at
least once.
3.4. Viral status at presentation
The majority of women were unaware of their HIV
(60.4%), HBV (58%), or HCV (56.2%) status at the time
they met the DLM. All were offered viral testing as part of
the routine prenatal work-up and the majority agreed to this.
Subsequently, six women (6.3%) were HIV positive, four
women (4.2%) were HBV positive, and 67 women (69.8%)
were HCV positive.
3.5. Psychiatric co-morbidity
Data on psychiatric co-morbidity was not routinely
collected. Nonetheless, 39 women (42.9%) reported that
they had a past history of depression. None reported aTable 1
Mean
Standard
deviation Range
Age 24.07 4.51 17–38
Age leaving education
in years
15.74 1.37 12–18
Age at first heroin
use in years
18.33 4.13 9–32
Duration of injecting
heroin use in months
20.61 29.49 0–108
Methadone dose at
presentation in mg
41.65 23.54
0–90
Methadone dose at
delivery in mg
39.30 23.84 0–95history of psychosis. Fourteen women (16.5%) had had at
least one admission to an in-patient psychiatric unit. Seven
women (8.2%) were attending a General Adult Psychiatry
OPD at initial presentation.
3.6. Stabilization of drug use
Fifty-three women (53.5%) were assessed initially as
being unstable in terms of their opioid use, 31 women
(32.3%) were offered admission to a specialist inpatient
Drug dependency unit to stabilize, and 26 of those women
were actually admitted. The mean duration of stay was
4.89 days (range 1–49 days). All returned to outpatient
treatment. Twenty-one women (24.7%) were assessed as
needing stabilization of their benzodiazepine use. Of these
21 women, 17 (20.2%) were admitted to the specialist unit
to detoxify from benzodiazepines. Their mean duration of
stay was 3.72 days (range 1–44 days). In total, 11 women
discontinued their benzodiazepines and ten women achieved
a reduction of their prescribed doses.
3.7. Prenatal care
Mean gestation at the index appointment in the CWH
was 18.44 weeks (range 7–35). Thirty-one women (45.6%)
were seen at or before sixteen weeks. Prenatal attendance
was recorded as being satisfactory (five or more visits) in
56 (62.9%) women, and as being unsatisfactory in
29 (32.6%) women, using criteria employed by the CWH.
3.8. Obstetric outcomes
There were no maternal deaths. Thirteen women (12.7%)
had caesarean sections. The percentage of caesarean sec-
tions in our cohort (12.7%) is lower than the corresponding
percentage for the CWH in 1999 at 16.3% of all births
(Coombe Women’s Hospital, 2000, p. 10).
3.9. Neonatal outcomes
The mean gestation at delivery was 38.45 weeks (range
17–43 weeks). The mean birth weight of the babies was
2948.91 g (range 1130.00–4120.00, SD = 608.47). Twelve
infants (10.5%) were delivered at a gestational age of less
than 37 weeks, i.e. premature. This compares with an
overall percentage of 5.8% for babies delivered prematurely
in CWH for 1999 (Coombe Women’s Hospital, 2000, p. 13)
and 5.9% of all births in 1998 (Coombe Women’s Hospital,
1999, p. 13). It is less than previous UK estimates of the
prevalence of prematurity among the offspring of pregnant
drug dependent women at 20% to 33% (Klenka, 1986). This
cohort had 2 infants born at less than 28 weeks (1.8%) and
10 infants born between 28 and 36 weeks (8.8%). Figures
for 1999 from the CWH show 0.3% of children born at less
than 28 weeks gestation and 5.5% born between 28 and
36 weeks. There was one late neonatal death at 28 days.
Table 2
Relationship between methadone dose level and neonatal withdrawal
Infant withdrawals
Yes No
Methadone dose at delivery n % n %
Low (5–30 mg) 8 27.6% 21 72.4%
Medium (31–50 mg) 12 42.9% 16 57.1%
High (51–95 mg) 20 71.4% 8 28.6%
All 40 47.1% 45 52.9%
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pathological diagnosis was not established.
3.10. Special Care Baby Unit admission
Forty-four babies (42.7%) of this entire cohort were
admitted to the Special Care Baby Unit. Sixteen of these
(15.7%) had a principal diagnosis of Neonatal Abstinence
Syndrome (NAS), 13 (12.7%) had a diagnosis of NAS with
a co-existing medical problem, 5 (4.9%) were admitted
solely because of problems associated with their premature
status, and 9 (8.8%) had other medical diagnoses. One baby
did not have a recorded diagnosis. The mean length of stay
was 5.88 days (range 1–117 days). The latter stay was an
extreme outlier for a baby born at 22 weeks gestation.
3.11. Maternal methadone dose and neonatal withdrawals
Of this cohort of women, 85 (75%) were being pre-
scribed methadone at the time of delivery and their infants’
withdrawal status was known. We recorded maternal metha-
done dose at delivery, alcohol and tobacco use status and the
presence of positive urinalysis for other opioids, benzodia-
zepines and cocaine, 1 month pre-delivery, with a view to
examining the risk factors for infant withdrawals. Because
only three women were non-smokers and three used co-
caine, these variables were omitted from the analysis.
We were aware that the treatment received by the mother
could influence the likelihood of neonatal withdrawal and
therefore recorded a rating of adequacy of maternal atten-
dance at prenatal appointments (as recorded by the obstetric
service) and whether the mother had been admitted to a
specialist inpatient unit for opioid or benzodiazepine stabi-
lization. Maternal methadone doses, which ranged from 5 to
95 mg, were classified into three levels for the analysis,
each containing a similar number of women: Low: n = 29
(5–30 mg), Medium: n = 28 (31–50 mg) and High: n = 28
(51–95 mg). Gestation was also classified into three levels:
Early (23–37 weeks), On time (38–40 weeks) and Late
(41 weeks+).
Forty infants (47%) received a diagnosis of Neonatal
Abstinence Syndrome using the Finnegan neonatal absti-
nence scoring system (Finnegan, Connaughton, Kron, &
Emich, 1975). Women whose infants had withdrawals had
a median methadone dose at delivery of 52.5 mg (Interquar-
tile range: = 40.0–63.7 mg) compared to a mean dosage of
34.0 mg (Interquartile range: = 20.0–45.0 mg) for those
methadone maintained women whose babies did not exhibit
withdrawal, a highly significant difference (Mann-Whitney
U = 498.5, p < .001). The chi-square test for trend indicated
that there was a significant dose-response relationship be-
tween maternal methadone dose at delivery and the occur-
rence of withdrawals (m2 = 10.825, df = 1, p = .001).
Respectively, withdrawal occurred in 28% (8/29), 43%
(12/28) and 71% (20/28) of infants delivered to women at
low, medium, and high doses ( Table 2).Withdrawals occurred in, respectively, 29% (5/17), 49%
(21/43) and 52% (11/21) of infants delivered early (<38
weeks), on time (38–40 weeks) and late ( > 40 weeks).
However, this graded relationship was not statistically
significant. The presence of opioids other than methadone
in the month pre-delivery and the mother’s alcohol use
status were not related to the occurrence of infant with-
drawal. However, a significant association was found be-
tween infant withdrawal and mother’s benzodiazepine use
(m2 = 4.377, df = 1, p < .05). Withdrawals occurred in 59%
(20/34) of cases where the mother tested benzodiazepine-
positive in the month preceding delivery compared to 33%
(11/33) of cases where the mother tested negative.
None of the associations between frequency of with-
drawal and adequacy of prenatal appointment attendance,
admission for benzodiazepine stabilization or for opioid
stabilization was statistically significant.
Multivariate logistic regression ( Table 3) indicated that
benzodiazepine use was not independently associated with
withdrawal (adjusted OR = 1.704, 95% CI: 0.554–5.238),
whereas high maternal methadone dose at delivery remained
a significant risk factor (adjusted OR = 4.862, 95%
CI: 1.166–20.273).
3.12. Discharge home and neonatal followup
All infants were discharged in the custody of their birth
mothers. Only 11 (11.5%) women returned with their babies
for a developmental check up at 4 months. Limited infor-
mation was available on the prevalence of neurodevelop-
mental problems in this group. Of the 11 babies who
returned to the Developmental Clinic, six were noted to
have developmental problems and four of these were
recorded as central nervous system-related.4. Discussion
This paper extends our knowledge of pregnant opioid
dependent women by describing a sample who received
prenatal care from a specialized Drug Liaison Midwife
service associated with the Coombe Women’s Hospital in
Dublin, Ireland. Though purely descriptive at this point, the
findings suggest benefits associated with this service model
and helps establish that effective working relationships are
Table 3
Results of separate and multivariate logistic regression analyses to assess the risk of withdrawal
Variable Crude OR 95% CI Adjusted OR 95% CI
Maternal methadone dose (ref. Low: 5–30 mg) 1.000 1.000
Medium: 31–50 mg 1.969 0.651–5.950 2.401 0.633–9.101
High: 51–95 mg 6.563 2.066–20.842 4.862 1.166–20.273
Gestation (ref. Early: <38wks) 1.000
On time: 38–40 wks 2.290 0.688–7.620
Late: 41 wks+ 2.639 0.684–10.175
Antenatal appt. attendance (ref. Average/above average) 1.000
Below average 1.558 0.579–4.195
Alcohol (ref. abstainers) 1.000
Alcohol drinker 0.867 0.339–2.219
Benzodiazepines* (ref. tested negative) 1.000 1.000
Tested positive 2.857 1.056–7.727 1.704 0.554–5.238
Opioids* (ref. tested negative) 1.000
Tested positive 1.448 0.572–3.665
Admission for benzodiazepine stabilisation (ref. No) 1.000
Yes 1.929 0.653–5.692
Admission for opioid stabilisation (ref. No) 1.000
Yes 0.485 0.133–1.767
* Tested one month pre-delivery.
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Obstetric and Drug Services involved in their care. The
analysis also suggests a positive association between mag-
nitude of maternal methadone dose and likelihood of
neonatal withdrawal.
Substance users are universally unpopular with the public
and even with health professionals. There is a substantial
literature on the negative perceptions about women who are
drug dependent and in particular those who are dependent
and pregnant. Stigma is a reality for many of these women
and impedes their appropriate care (Crisp, Gelder, Rix,
Meltzer, & Rowlands, 2000). It was envisaged that the
creation of a specialist Drug Liaison Midwife would assist
in the reduction of the stigma associated with the treatment
of pregnant female drug users, ease access to care for
pregnant dependent women and help maintain care path-
ways once established (Scully, Geoghegan, & Keenan,
2001). It was also envisaged that the post would facilitate
better communication and working relationships among the
professional staff involved in the care of this patient
population. The experience of these DLMs suggests that
this is a feasible and attainable aim.
Most of the women were enlisted in the antenatal care
through their involvement with the Drug Treatment services.
All but one of the women were retained in Drug treatment
throughout the course of their pregnancies. The majority of
the women stabilized on methadone. A minority however
remained quite difficult to stabilize on an outpatient basis.
Admission to a specialist drug dependency unit helped
many of them but a minority (35 women (36.1%) in the
month pre-delivery and 17 women (18.7%) in the week pre-
delivery) remained opioid positive.
The obstetric and neonatal outcomes appear generally in
line with other European/UK studies where a dedicated
service is provided for pregnant opioid dependent women(Myles, 2000) and significantly better than in studies of
cohorts of pregnant drug dependent women where no
specialist service exists. The level of prematurity (10.5%
with a gestational age below 37 weeks) is lower than the
range (20–33%) commonly quoted in the literature (Klenka,
1986), but obviously remains of concern.
Although the case for methadone maintenance in preg-
nancy is now well established (Ward, Hall, & Mattick,
1999) and it is accepted that for the majority of opioid
dependent pregnant women (Fisher, 2000), there exist
continuing concerns about the relationship between mater-
nal methadone dose and the subsequent development of
neonatal withdrawal.
Unfortunately, there is no agreement in the professional
literature in respect of the putative association between
maternal methadone dose and neonatal withdrawals. The
area is controversial and tends to be viewed through the
prism of the ‘‘maintenance vs. abstinence debate’’ in respect
of substitution therapy (Jarvis & Schnoll, 1995). Jarvis and
Schnoll reviewed the available evidence in a National
Institute on Drug Abuse monograph. They noted that a
number of North American, Australian, and European
studies supported the positive association between metha-
done dose and likelihood of neonatal withdrawal. They cited
studies by Davis, Chappel, Mejia-Zelaya, and Madden in
1975 from the Illinois Drug Abuse Programme, Madden and
colleagues in 1977 (n = 110 women), and Doberzak,
Kandall, and Friedman in 1993 (n = 21) that supported
the contention that a positive relationship exists. A UK
study by Dawe, Gerada, and Strang (n = 35) published in
1992 also noted a positive correlation between maternal
methadone dose and neonatal withdrawals.
Studies with negative findings were also noted in the
Jarvis and Schnoll’s NIDA review (1995): Harper, Solish,
Purow, Sang, and Panepinto (1974) in New York did not
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methadone dose and neonatal withdrawal. Nor did a later
study by Kandall and colleagues (1977). Subsequent studies
by Brown et al. (1998) and Berghella et al. (2000) did not
find evidence of a positive correlation between maternal
methadone dose and neonatal withdrawals. Berghella and
colleagues noted that in a retrospective review of 51 pregnant
opioid dependent women attending their institution between
9/96 and 9/97 with a mean maternal methadone dose of
83.4 mg (range 30–165 mg) before delivery that high
maternal methadone doses might not significantly worsen
neonatal withdrawal compared to lower doses.
More recently a paper by Dashe and colleagues (2002)
described a retrospective cohort study of 70 pregnant opioid
dependent women attending their facility in Texas, USA.
They described a significant relationship between maternal
methadone dose and neonatal withdrawal. In a UK setting a
paper by Johnson, Greenough, and Gerada (2003) examin-
ing 41 admissions to a tertiary neonatal intensive care unit in
London demonstrated that mothers who took methadone
and other illicit substances in pregnancy had significantly
longer neonatal admissions than infants of women with
other types of drug use.
It is apparent that the field is divided on the issue of a
relationship and the significance to attach to this relation-
ship, should it be demonstrated. Every decision to prescribe
any pharmacologically active agent represents the end point
of a process of decision making where the potential risks
and benefits in addition to the patient’s views on the matter
are weighed, considered, and a recommendation made.
Neonatal withdrawals are a treatable complication of oral
substitution therapy, whereas prematurity, low birth weight
and seroconversion for either HCVor HIV have much more
serious implications for the infant’s future health.5. Limitations
While this is one of the largest series reported to date in
the literature, involving a single Dublin maternity hospital,
there are a number of limitations to this analysis. First, the
analyses are subject to the methodological shortcomings
associated with a retrospective chart based survey. The
survey instrument was developed locally and is not a
standardized instrument. Many variables in the dataset were
missing, also reducing the specificity of our findings.
Several variables not measured or analyzed may have acted
as confounding factors (e.g. maternal smoking status, as all
but three women smoked) and we were not in a position to
control for these. Self selection by our patients, may have
biased the results of the analysis. That is, these findings may
not extend to pregnant women dependent upon other sub-
stances, or to pregnant opiate dependent women who did not
seek pre-natal care.
As noted care was tailored individually according to
perceived need and individual choice, methadone doseswere decided collaboratively by the prescribing doctor and
the woman concerned on the basis of self reported with-
drawals, observed withdrawal symptoms, and the results of
regular urine toxicology. Finally the ethos of the service was
to encourage stabilization of drug use and engagement with
pre-natal and social care. There was a possibility of bias in
the formulation of a diagnosis of neonatal withdrawals on
the part of the treating clinicians; this was limited by the
regular use of a validated instrument in making the diagno-
sis of neonatal withdrawals.
In summary, the experience of this specialized Drug
Liaison Midwife liaison service indicates that it is possible
to build effective working relationships between drug
dependent pregnant women, the obstetric services, and
the drug treatment services involved in their care. The
obstetric and neonatal outcomes of this population appear
to have improved with the introduction of this specialized
service with benefit to these mothers, their infants and to
the health care system—although this suggestion remains
tentative since our study did not involve a control group of
similar patients who did not receive the DLM service. We
believe that our experience with Drug Liaison Midwife
service adds support for a policy of developing similar
liaison posts in other drug treatment services where there
are significant numbers of pregnant drug-using women.Acknowledgments
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